This trial is evaluating whether Losartan will improve 1 primary outcome and 3 secondary outcomes in patients with Fibrosis. Measurement will happen over the course of after 1 year of losartan treatment..
This trial requires 24 total participants across 1 different treatment group
This trial involves a single treatment. Losartan is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"The prevalence of HbA(1c>6.0%) ≥6% (37%) is lower than the previous reports for anemia. The prevalence of sickle cell disease is similar to previous estimates. However, the prevalence of sickle cell disease with abnormal HbA(1c) is underestimated." - Anonymous Online Contributor
"This report highlights the high prevalence of SCD (8%) in an urban population which may be due to lack of prenatal screening. This high prevalence suggests that the prevalence is under-reported in this area." - Anonymous Online Contributor
"Results from a recent clinical trial of this controlled trial indicate that iron chelation therapy for sickle cell anemia improves hemoglobin and decreases red cell losses." - Anonymous Online Contributor
"The cause for anemia, sickle cell, is unknown. However, sickle cell disease is linked to environmental factors, such as dehydration, and genetic factors such as sickle cell trait. Sickle cell disease and sickle cell trait are thought to result from environmental as well as inheritable factors.\n" - Anonymous Online Contributor
"Treatments for sickle cell anemia includes oxygen therapy, blood transfusions, and blood transplants. The exact timing and method of transfusion is dependent on the type of anemia encountered and the number of units of blood required. If less transfusions are necessary, one to two units of whole blood can be given by the use of photopheresis, an inexpensive and effective way of collecting the desired units of platelets. Hematopoietic stem cell transplantation therapy is a new method for sickle cell anemia treatment; however, the potential for complications remains, including transplant rejection and immune reconstitution inflammatory Syndrome (IRIS)." - Anonymous Online Contributor
"Anemia is a common complication of sickle cell disease and affects more than one-quarter of patients. The pathophysiology of anemia and its clinical significance still remain unclear. This review highlights the important clinical relevance of anemia as well as its relevance and severity in sickle cell disease." - Anonymous Online Contributor
"If you're not a member of the medical community, read this article in your community's newspaper to see how common anemia is. If you are concerned about your children, then read below. It should be a concern to every person in our communities to [have your children screened for anemia and sickle cell disease] if they have unexplained vomiting or dizziness, because both of these are signs of anemia. To [have your children screened for anemia and sickle cell disease] is to find the cause of these problems and to treat them. By doing this, [you've improved the chance] that your children will live a healthier life than they might otherwise." - Anonymous Online Contributor
"Women without other comorbidities will likely be the largest group who benefits from treatment. Men will benefit most dramatically if they are symptomatic, are older, are symptomatic with more pain, and are symptomatic with a hemoglobin of less than 10 and 10-11 g/dL. The best way to identify whom will benefit from treatment is by considering these criteria and talking with a doctor who specializes in treating people with anemia and sickle cell disease." - Anonymous Online Contributor
"Losartan causes a reduction in hemoglobin concentration regardless of the presence of anemia from sickle cell trait. It has also been shown to relieve the anemia-associated symptoms of mild sickle-cell disease in rats. Both these pharmacodynamic or pharmacokinetic effect of losartan on hemoglobin concentration are responsible for the beneficial effects of losartan on sickle-cell disease." - Anonymous Online Contributor
"The long-term use of losartan is associated with an increased risk of mortality and heart failure as compared to atorvastatin. The current findings suggested that losartan has no more advantages to minimize mortality compared to statin." - Anonymous Online Contributor
"All cases must be evaluated. In this type of situation, the possibility of iron deficiency can't be neglected. An erythro-siderophilic anemia with no demonstrable underlying cause is also a factor. Hemoglobin levels, if abnormal, must be taken into consideration. It is difficult to distinguish an iron deficiency anemia from a hemoglobinopathy, although the bone marrow might show a marked increase in iron." - Anonymous Online Contributor
"This review shows that most studies were small, and that the majority of these studies were blinded. Consequently, any definitive conclusions about the effectiveness of losartan alone or in combinations with other treatments or the adverse effects of losartan must await a large randomised controlled trial." - Anonymous Online Contributor